<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="131733" href="/d/html/131733.html" rel="external">see "Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Drug information"</a> and <a class="drug drug_patient" data-topicid="131760" href="/d/html/131760.html" rel="external">see "Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F56714051"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Sotrovimab Distribution Update</span>
<span class="collapsible-date">updated April 2022</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA and Health and Human Services (HHS) have announced that sotrovimab is no longer authorized for use to treat COVID-19 in any US region as it is unlikely to be effective against the Omicron BA.2 subvariant, which is now estimated to account for &gt;50% of COVID-19 cases in the US.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-sotrovimab-emergency-use-authorization&amp;token=O9V9878Fi9FN%2F%2BH4%2BWSwYgdgXvPdqXXjMqBECWJ%2Bx76X1M%2Bp3wXOIz6Nmg3X5aUzacsYrer%2BlKcnQHrEjMW4gbor%2F2MmQTGJQUgaBBHGaoVpXH7hyLbXuyVO9xxlC74K&amp;TOPIC_ID=131734" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization</a> and <a href="/external-redirect?target_url=https%3A%2F%2Fwww.phe.gov%2Femergency%2Fevents%2FCOVID19%2Finvestigation-MCM%2FSotrovimab%2FPages%2Fdefault.aspx&amp;token=viNEVcpuOWpqPfys6RBiOfDqDGL1VHOjOJTnOaqnGF1hcS%2BaH8fNsGOgq%2BqW13whXE4%2BYPnPvS9R0Loc6s46XDnDXszcYRYaj16K2BpTX3mtDejutaG4EGOHPOi7mMBh&amp;TOPIC_ID=131734" target="_blank">https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Sotrovimab/Pages/default.aspx</a>.</p>
<p style="text-indent:0em;">In Canada, Health Canada has announced that sotrovimab is unlikely to maintain efficacy against the Omicron BA.2 subvariant, and health care professionals are advised that local epidemiology and individual exposure to variants should be taken into consideration before use of sotrovimab.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Frecalls-rappels.canada.ca%2Fen%2Falert-recall%2Fsotrovimab-injection-risk-treatment-failure-due-circulation-sars-cov-2-omicron-ba2&amp;token=mU%2Fu83QmZQunVV5Y7o0dMyR%2F6I7BYUFnDsGxlnEEd9wyeXZsAWHRmYjmjaOKXcZQ6s4hX%2FnD0Xevt3G32i1%2FDzUIJJUOZYC7ZclcidThOTw%2FoEYk54yZnomBxSBcAVskTlPqUhZYeBkR5WxNm72Hxw%3D%3D&amp;TOPIC_ID=131734" target="_blank">https://recalls-rappels.canada.ca/en/alert-recall/sotrovimab-injection-risk-treatment-failure-due-circulation-sars-cov-2-omicron-ba2</a>.</p></div>
</div>
</div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55809185"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F55819080"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider local prevalence of SARS-CoV-2 variants when evaluating treatment options; sotrovimab is not authorized for use in geographic regions where infection is likely to be due to a nonsusceptible variant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). Further information on variants may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=131734" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f2cd662-970c-4405-bbca-4a27559f302b">COVID-19, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only for use in patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents weighing ≥40 kg: IV: 500 mg as a single dose; administer as soon as possible after a positive SARS-CoV-2 test and within 7 days of symptom onset. <b>Note:</b> Sotrovimab has not been studied in pediatric patients; emergency use authorization from the FDA is based on likelihood of similar exposures in patients ≥12 years of age weighing ≥40 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55819081"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥12 years and Adolescents weighing ≥40 kg: IV: No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F55819082"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the fact sheet for health care providers (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55819196"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="131733" href="/d/html/131733.html" rel="external">see "Sotrovimab (Canada: Authorized; United States: Authorization withdrawn): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f2cd662-970c-4405-bbca-4a27559f302b">COVID-19, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, mild to moderate (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with positive SARS-CoV-2 direct viral testing who are at high risk for progression to severe disease or hospitalization; refer to the FDA fact sheet for health care providers for more information on patients at high risk for progression to severe disease. Use is not authorized for patients who are hospitalized or require new or increased oxygen therapy due to COVID-19; outcomes may be worse if used in patients requiring high-flow oxygen or mechanical ventilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-IDSA.1','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-IDSA.1','lexi-content-ref-NIH.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>500 mg as a single dose; administer as soon as possible after a positive SARS-CoV-2 test and within 7 days of symptom onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).<b> Note: </b>Consider local prevalence of SARS-CoV-2 variants when evaluating treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-IDSA.1','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-IDSA.1','lexi-content-ref-NIH.1'])">Ref</a></span>). Further information may be found at: <a href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=131734" target="_blank">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55819198"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F55819199"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F56136679"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reactions,</b> including <b>anaphylaxis</b> and <b>infusion related reactions</b>, have occurred with sotrovimab. Reactions may be severe or life threatening. Infusion related reactions may include arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, hypotension, hypertension, bronchospasm, difficulty breathing, altered mental status, angioedema, throat irritation, rash (including urticaria), and vasovagal reactions (eg, presyncope, syncope), among other reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Immediate hypersensitivity reactions (eg, anaphylaxis): Non–dose-related; immunologic; IgE-mediated with specific antibodies formed against a drug allergen (Blumenthal 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions (eg, anaphylaxis): Rapid; IgE-mediated reactions generally occur within 1 hour of administration but may occur up to 6 hours after exposure (Blumenthal 2019, NICE 2014). Infusion related reactions: Rapid; occurred during the infusion and up to 24 hours after the infusion of sotrovimab.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55830691"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse reactions and incidences are derived from the FDA issued emergency use authorization (EUA) unless otherwise specified. Refer to EUA for information regarding reporting adverse reactions (FDA 2022). Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction (including severe hypersensitivity reaction), type 1 hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (including severe infusion related reaction)</p></div>
<div class="block coi drugH1Div" id="F55808912"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylaxis to sotrovimab or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to sotrovimab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55819191"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reaction, including anaphylaxis, may occur with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions (eg, fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia [eg, atrial fibrillation, sinus tachycardia, bradycardia], chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vasovagal reactions [eg, presyncope, syncope], dizziness, diaphoresis) have been observed with administration of sotrovimab and up to 24 hours after the infusion. These reactions may be severe or life threatening. If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiviral resistance: Development of SARS-CoV-2 variants with reduced susceptibility to sotrovimab may potentially increase risk of treatment failure; consider local prevalence of SARS-CoV-2 variants, if available, when evaluating treatment options (FDA 2022; NIH 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Sotrovimab may only be administered in health care settings in which health care providers have immediate access to medications to treat a severe infusion or hypersensitivity reaction, such as anaphylaxis, and the ability to activate the emergency medical system, as necessary (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical worsening: Clinical worsening of COVID-19, including signs or symptoms of altered mental status, arrhythmia (eg, atrial fibrillation, bradycardia, tachycardia), fatigue, fever, hypoxia, or increased respiratory difficulty, has been reported after administration of SARS-CoV-2 monoclonal antibodies; some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to COVID-19 progression (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Sotrovimab is not authorized for use in patients who are hospitalized due to COVID-19, require oxygen therapy due to COVID-19, or require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID related comorbidity. Benefit of treatment has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen therapy or mechanical ventilation (FDA 2022).</p></div>
<div class="block prod-avail drugH1Div" id="F55808940"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;">Investigational agent; approved for emergency use authorization by the FDA May 2021.</p></div>
<div class="block foc drugH1Div" id="F55920730"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/8 mL (8 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F55920729"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F55989140"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sotrovimab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/8 mL (per mL): $315.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56319078"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/8 mL (8 mL)</p></div>
<div class="block accres drugH1Div" id="F55819185"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Sotrovimab is not commercially available; it is available as part of ongoing clinical trials and under an emergency use authorization (EUA) from the FDA. The Department of Health and Human Services will determine weekly distribution amounts for each state/territory based on weekly reports of new COVID-19 cases and hospitalizations, in addition to data on inventories and use submitted to the federal government. State and territorial health departments will identify which sites in their respective jurisdictions receive product as well as the amount they will receive.</p>
<p style="text-indent:0em;">As part of the EUA, fact sheets pertaining to emergency use of sotrovimab are required to be available for health care providers and patients/caregivers, and certain mandatory requirements for sotrovimab administration under the EUA must be met as outlined in the FDA EUA letter; the fact sheets and EUA letter may be accessed at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19&amp;token=rq0v7UA%2FaaVGAQ43lP4VeyO71d76WAi6fAerSlxWKr%2FBrhHPPa6XRPELZ6Kbf03ksugzouTEqv9n23RxD5EyYVD57jZ3I%2B6SwCnhNM72ixPRe6Si7f48ovDjFhAB8L6HRJsHGtio84n9rfzv5LmD%2FjFSky%2BL8yCEAk2uKYVGsIg%3D&amp;TOPIC_ID=131734" target="_blank">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19</a>. Additionally, health care providers must track and report all medication errors and serious adverse events potentially associated with sotrovimab use by either submitting a MedWatch form (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedwatch%2Freport.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPNcm5lNJ%2BSfidIV4m5OTN5Ih2EApxCjHbBkH0Y1jxFob&amp;TOPIC_ID=131734" target="_blank">https://www.fda.gov/medwatch/report.htm</a>) or FDA Form 3500 (health professional) by mail or fax (1-800-FDA-0178); a copy of all MedWatch forms should also be provided to GlaxoSmithKline.</p></div>
<div class="block admp drugH1Div" id="F55827692"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Must be diluted prior to administration. If diluted solution is refrigerated following preparation, allow solution to come to room temperature (~15 minutes) prior to administration. After priming with NS, administer as an IV infusion through a PVC or polyolefin (PO) infusion set; it is strongly recommended to use a 0.2 micron polyethersulfone filter. Infusion duration is dependent on size of infusion bag used:</p>
<p style="text-indent:-2em;margin-left:2em;">50 mL infusion bag: Infuse over 15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">100 mL infusion bag: Infuse over 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Infuse the entire content of the bag to avoid underdosage; flush line with NS following completion of infusion. Slow or interrupt infusion and treat as appropriate if the patient develops any signs of infusion-associated events (eg, fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia, chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness, diaphoresis); if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and provide emergency care (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F55819200"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> If diluted solution is refrigerated prior to administration, allow solution to warm to room temperature for ~15 minutes prior to administration. Administer as an IV infusion over 15 minutes for 50 mL infusion bag or over 30 minutes for 100 mL infusion bag; administer through a PVC or polyolefin infusion set containing a 0.2-micron polyethersulfone filter. Due to potential overfill of prefilled saline bags, the entire infusion solution in the bag should be administered to avoid underdosage. Slow or stop infusion and treat as appropriate if an infusion-related reaction occurs. Flush infusion line with D5W or NS following completion of infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F55819193"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Refrigerate intact vials at 2°C to 8°C (36°F to 46°F); protect from light. Do not freeze or shake (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Diluted infusion solution should be administered immediately. If immediate administration is not possible, store diluted sotrovimab infusion solution for up to 24 hours refrigerated at 2°C to 8°C (36°F to 46°F) or up to 6 hours at up to 25°C (77°F), including transportation and infusion time. If refrigerated, allow infusion solution to warm to room temperature for ~15 minutes prior to administration (FDA 2022).</p></div>
<div class="block usep drugH1Div" id="F55808998"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Investigational agent for treatment of mild to moderate COVID-19 in patients with positive SARS-CoV-2 direct viral testing who are at high risk for progressing to severe COVID-19, including hospitalization or death (FDA issued emergency use authorization [EUA] in ages ≥12 years weighing ≥40 kg and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Per the EUA, the following factors, in addition to other potential factors (eg, race, ethnicity), may place patients at high risk for progressing to severe COVID-19 (FDA 2022):</p>
<p style="text-indent:-2em;margin-left:4em;">• Overweight or obesity (eg, BMI &gt;25 kg/m<sup>2</sup>; BMI ≥85th percentile for age and gender, based on CDC growth charts, for those 12 to 17 years of age)</p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression (due to treatment or underlying disease)</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease (including congenital heart disease) or hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic lung diseases (eg, chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)</p>
<p style="text-indent:-2em;margin-left:4em;">• Sickle cell disease</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurodevelopmental disorders (eg, cerebral palsy) or other conditions that confer medical complexity (eg, genetic or metabolic syndromes, severe congenital anomalies)</p>
<p style="text-indent:-2em;margin-left:4em;">• Medical technology dependence (eg, tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19])</p>
<p style="text-indent:-2em;margin-left:4em;">• Older age (eg, ≥65 years)</p>
<p style="text-indent:-2em;margin-left:2em;">Sotrovimab is NOT authorized for use in patients who are hospitalized due to COVID-19, for patients who require new or increased oxygen therapy due to COVID-19, or for use in geographic regions where infection is likely to be due to a nonsusceptible variant (FDA 2022).</p></div>
<div class="block cyt drugH1Div" id="F55840520"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55840517"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56394829"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Reproductive toxicity studies have not been conducted (FDA 2022).</p></div>
<div class="block pri drugH1Div" id="F55819189"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Reproductive toxicity studies have not been conducted (FDA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Sotrovimab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of sotrovimab during pregnancy are available (Aberumand 2022; AlKindi 2022; Crispino 2023; Frallonardo 2023; Gupta 2022; McCreary 2022; Tuan 2023). The potential benefits or risks of in utero exposure to sotrovimab to the fetus are not known (FDA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">The risk of severe morbidity and mortality from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients. Pregnant and recently pregnant patients with moderate or severe infection are at increased risk of complications such as hypertensive disorders of pregnancy, postpartum hemorrhage, or other infections compared to pregnant patients without COVID. Symptomatic pregnant patients may require ICU admission, mechanical ventilation, or ventilatory support (ECMO). Other adverse pregnancy outcomes include preterm birth and stillbirth. The risk of coagulopathy, cesarean delivery, and maternal death may be increased; neonates have an increased risk for NICU admission. Maternal age and comorbidities such as diabetes, hypertension, lung disease, and obesity may also increase the risk of severe illness in pregnant and recently pregnant patients (ACOG 2023; NIH 2022).</p>
<p style="text-indent:0em;margin-top:2em;">In general, the treatment of COVID-19 infection during pregnancy is the same as in nonpregnant patients; however, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process (NIH 2022). Dose adjustments are not recommended for patients who are pregnant (FDA 2022). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to sotrovimab is ongoing. Pregnant and recently pregnant patients exposed to sotrovimab are encouraged to enroll in the pregnancy registry (1-800-616-3791 or https://covid-pr.pregistry.com).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor maternal and infant outcomes following exposure to COVID-19 during pregnancy is ongoing. Health care providers are encouraged to enroll patients exposed to COVID-19 during pregnancy in the Organization of Teratology Information Specialists (OTIS) pregnancy registry (1-877-311-8972; https://mothertobaby.org/join-study/).</p></div>
<div class="block mopp drugH1Div" id="F55819085"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for infusion-related reactions (eg, fever, chills, hypotension, rash, pruritus) and hypersensitivity/anaphylaxis during infusion and for 1 hour following infusion completion (FDA 2022).</p></div>
<div class="block pha drugH1Div" id="F55819195"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Sotrovimab is a recombinant human IgG1k monoclonal antibody that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. Sotrovimab inhibits an undefined step that occurs after virus attachment and prior to fusion of the viral and cell membranes (FDA 2022).</p></div>
<div class="block phksp drugH1Div" id="F55827690"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clinical trials have not been performed; serum exposures in patients ≥12 years of age and weighing ≥40 kg are expected to be similar to those observed in adults (FDA 2022).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56755129"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Xevudy</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36244996">
<a name="36244996"></a>Aberumand B, Kamal R, McKinney B, Betschel S. Monoclonal antibody treatment of COVID-19 in a pregnant woman with common variable immunodeficiency. <i>Allergy Asthma Clin Immunol</i>. 2022;18(1):91. doi:10.1186/s13223-022-00730-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/36244996/pubmed" id="36244996" target="_blank">36244996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35135972">
<a name="35135972"></a>AlKindi F, Chaaban A, Al Hakim M, Boobes Y. Sotrovimab use for COVID-19 infection in pregnant kidney transplant recipient. <i>Transplantation</i>. 2022;106(5):e277-e278. doi:10.1097/TP.0000000000004083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/35135972/pubmed" id="35135972" target="_blank">35135972</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetrician-gynecologists, obstetric. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed</i>
<i>Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IDSA.1">
<a name="IDSA.1"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated August 27, 2021. Accessed February 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front</i>
<i>Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37630512">
<a name="37630512"></a>Crispino P, Marocco R, Di Trento D, et al. Use of monoclonal antibodies in pregnant women infected by COVID-19: a case series. <i>Microorganisms</i>. 2023;11(8):1953. doi:10.3390/microorganisms11081953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/37630512/pubmed" id="37630512" target="_blank">37630512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36896940">
<a name="36896940"></a>Frallonardo L, Vimercati A, Novara R, et al. Use of sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience. <i>Pathog Glob Health</i>. 2023;117(5):513-519. doi:10.1080/20477724.2023.2188839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/36896940/pubmed" id="36896940" target="_blank">36896940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34706189">
<a name="34706189"></a>Gupta A, Gonzalez-Rojas Y, Juarez E, et al; COMET-ICE Investigators. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. <i>N Engl J Med</i>. 2021;385(21):1941-1950. doi:10.1056/NEJMoa2107934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/34706189/pubmed" id="34706189" target="_blank">34706189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35371772">
<a name="35371772"></a>Gupta I, Arguello Perez ES. Use of sotrovimab in a pregnant patient with COVID-19 infection. <i>Cureus</i>. 2022;14(2):e22658. doi:10.7759/cureus.22658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/35371772/pubmed" id="35371772" target="_blank">35371772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36375150">
<a name="36375150"></a>McCreary EK, Lemon L, Megli C, Oakes A, Seymour CW; UPMC Magee Monoclonal Antibody Treatment Group. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. <i>Ann Intern Med</i>. 2022;175(12):1707-1715. doi:10.7326/M22-1329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/36375150/pubmed" id="36375150" target="_blank">36375150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. <a href="https://www.covid19treatmentguidelines.nih.gov/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/</a>. Updated February 24, 2022. Accessed February 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sotrovimab.1">
<a name="Sotrovimab.1"></a>Sotrovimab [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37101135">
<a name="37101135"></a>Tuan JJ, Sharma M, Kayani J, et al. Outcomes of pregnant women exposed to sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). <i>BMC Infect Dis</i>. 2023;23(1):258. doi:10.1186/s12879-023-08198-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sotrovimab-canada-authorized-united-states-authorization-withdrawn-pediatric-drug-information/abstract-text/37101135/pubmed" id="37101135" target="_blank">37101135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-EUA.PDF. Updated March 2022. Accessed March 25, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131734 Version 61.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
